Prevail Therapeutics and Switzerland-based Lonza entered into a strategic collaboration focused on the development of the baculovirus/Sf9 expression system for Prevail's pipeline of gene therapy programs aimed at neurodegenerative diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,